Akèy › Limfòm Non-Hodgkin › Texas
Etid klinik pou Limfòm Non-Hodgkin nan Texas
48 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Jiska laj 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT01853631Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Laj 12 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Laj 12 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT02917083T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Md Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT04728893A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Texas Southwestern, Dallas
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- The University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Sarah Cannon Research Institute at St. David's South Austin, Austin
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Sep 15, 2026 · NCT05798897A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Md Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07195916AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Houston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06137144Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Austin
- Research Site, Houston
- Research Site, San Antonio
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Baylor Scott & White Health, Temple
- Texas Oncology - Gulf Coast, The Woodlands
- Texas Oncology- Northeast Texas, Tyler
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06806033Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Baylor University Medical Center, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT03666000A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06393738TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- The University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07082803Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lumi Research, Kingwood
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
- Natera, Inc., Austin
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07750886Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- UT Southwestern Medical Center, Dallas
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- St. David's South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center, Fort Worth
- MD Anderson Cancer Center, Houston
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 15 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT02727803DALY II USA/ MB-CART2019.1 for DLBCL
- UT Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Transplant Institute, San Antonio
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- ak 5 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- ak 1 plis
Ap rekriteFaz 1
Tout laj · Tout sèks · Mizajou Jun 25, 2026 · NCT04664179IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
- University of Texas Southwestern Medical Center, Dallas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 8, 2026 · NCT06768905Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT05529069Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- The University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06876662Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Tout laj · Tout sèks · Mizajou Mar 2, 2026 · NCT01555892A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- UT Southwestern Medical Center, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 4, 2026 · NCT05892718Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Ut Southwestern, Dallas
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jan 22, 2026 · NCT06357754AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.